Project Grant R61NS131928
Award Date
8/1/24
Completion Date
6/30/26
Dollars Obligated
$1.7M
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $2,147,016 to Neurodex Inc. to advance the development of a novel blood-based biomarker for characterizing disease progression and therapeutic response in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), and related dementias....
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund a $1,049,035 initiative to harmonize and curate a natural history database for Metachromatic Leukodystrophy (MLD), a rare and fatal neurological disease. The award will support the creation of the "MLD-CORE" database, which will pool longitudinal medical records,...
This Project Grant award, titled "IDEAL-XAI: ADVANCING EXPLAINABLE AI TO IDENTIFY EARLY DRIVER EVENTS OF ALZHEIMER'S DISEASE," is funded by the National Institute on Aging (CFDA 93.866 - Aging Research) for $1,761,543 from August 15, 2024 to July 31, 2027. The award supports research to develop advanced explainable AI (XAI) methods that can generate biologically informed explanations of Alzheimer's disease (AD) progression. The objectives are to: 1) incorporate prior biological...
This Project Grant award, funded by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to develop high-performing, fair, and interpretable large language models (LLMs) to detect Alzheimer's disease (AD) and its precursor stages, Mild Cognitive Impairment (MCI), from transcribed unstructured speech samples. The $300,506 award, effective from Aug 1, 2024 to May 31, 2028, will test the use of fair and explainable LLMs to identify early stages of the AD trajectory, focusing on...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $532,381 to Emory University to comprehensively investigate the molecular mechanisms underlying the role of the KIF5A gene variant KIF5AΔE27 in the pathogenesis of amyotrophic lateral sclerosis (ALS). The research will involve three specific aims: 1) determining the...
This Project Grant award of $791,086 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop computational models that can predict the presence of non-Alzheimer's disease neuropathological changes (non-ADNC), such as Lewy body disease, TDP-43 proteinopathy, and cerebral amyloid angiopathy, in individuals with Alzheimer's disease neuropathological changes. The project will leverage autopsy-confirmed datasets, multimodal neuroimaging, and clinical data to build these...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) is focused on developing a new diagnostic test for Alzheimer's disease (AD) based on a neurotoxic amyloid-beta (Aβ) dimer. The $431,826 award was made on September 15, 2024, with an ultimate completion date of August 31, 2026. The key goals of the project are to elucidate the structure of a novel covalently crosslinked Aβ dimer found in the brains of AD patients, and to produce monoclonal...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $1,208,638 to Emory University to investigate the therapeutic potential of targeting NADH-reductive stress in mitochondrial diseases. The key objectives are to: (A) assess how an engineered enzyme called LOXCAT impacts metabolism and mitochondrial function in primary cell...
This Project Grant award, valued at $802,034 and funded by the National Institute on Aging's Aging Research program (CFDA 93.866), aims to develop a comprehensive "multimodal, multiscale and multistage systems biology (M3SB) infrastructure" to advance precision medicine for Alzheimer's disease (AD) and longevity research. The key objectives are to: 1) conduct multi-omics analyses to identify bioage-modifying targets and repurposable medicines for AD and related dementias; 2) build...
This federal Project Grant award for $2,307,075.00, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports innovative research aimed at defining novel mechanisms of neurodegenerative diseases and devising potential therapeutic strategies. The primary recipient, The Leland Stanford Junior University, will conduct genome-wide modifier screens in human...